DeepQure Participates in ‘ACC.26’ in the U.S., Full-Scale Global Expansion into Resistant Hypertension Treatment Market
- 3 days ago
- 2 min read
DeepQure participated in the American College of Cardiology Annual Scientific Session (ACC.26) held in New Orleans, USA, showcasing its next-generation technology for the world's first laparoscopy-based extravascular renal denervation (RDN).
ACC.26, held from March 28 to 30, is a major international conference where cardiology experts from around the world share the latest treatments and medical technologies. Through this participation, DeepQure promoted the uniqueness of its technology, expanded its global medical network, and established a foothold for market entry.
DeepQure’s core product, HyperQure™, is the world’s first laparoscopy-based extravascular RDN medical device, developed based on research by Professor Chang-Wook Jeong’s team at Seoul National University Hospital.
Unlike conventional methods that insert a catheter inside the blood vessel, HyperQure wraps around the renal artery from the outside via laparoscopy to block the sympathetic nerves. Its key feature is the ability to completely block the nerves without damaging the inner wall of the blood vessel, ensuring both therapeutic efficacy and safety. In a recently completed domestic pilot clinical trial, a blood pressure reduction effect of an average of 51 mmHg was confirmed 12 months after surgery.
DeepQure is accelerating multi-center clinical trials (IDE Clinical Trials) in the U.S. market for the global commercialization of HyperQure. Currently, clinical trials are underway at six major U.S. institutions, including:
Stanford University
Mayo Clinic
UC Irvine
University of Florida
Henry Ford Health System
Emory University
A representative from DeepQure stated, "We plan to promote our technological prowess by sequentially presenting the achievements confirmed in domestic and international clinical trials at prestigious international conferences such as the EuroPCR. We will realize the global commercialization of HyperQure by solidifying strategic partnerships with global medical device companies currently under discussion."